Iluvien

Fluocinolone acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal sustained‑release implant for intravitreal use. It provides long‑term anti‑inflammatory therapy for diabetic macular edema and non‑infectious posterior uveitis, conditions that affect the posterior segment of the eye in adult patients.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution. Our logistics network ensures timely delivery and temperature‑controlled handling where required.

Iluvien is used to manage ocular inflammatory conditions and retinal edema. - Diabetic macular edema: reduces retinal swelling and can improve visual acuity. - Non‑infectious posterior uveitis: controls intra‑ocular inflammation and helps preserve vision. - Uveitic macular edema: delivers continuous corticosteroid release to manage edema associated with uveitis.

Iluvien may cause ocular and systemic reactions.

Common Side Effects: - Increased intraocular pressure: may require monitoring or treatment. - Cataract formation: gradual lens opacity development. - Ocular discomfort: mild pain or irritation after implantation. - Vitreous floaters: perception of moving specks in vision. - Conjunctival hemorrhage: small bleeding spots on the eye surface. - Blurred vision: temporary visual acuity changes.

Serious or Rare Side Effects: - Endophthalmitis: intraocular infection requiring urgent care. - Retinal detachment: separation of retinal layers, a vision‑threatening emergency. - Implant migration: displacement of the device within the eye. - Persistent inflammation: ongoing ocular inflammation despite therapy. - Optic nerve damage: rare loss of optic nerve function. - Systemic corticosteroid effects: possible systemic absorption leading to adrenal suppression.

Prior to Iluvien implantation, clinicians should assess ocular health and patient history. - Intraocular pressure monitoring: check baseline and follow‑up IOP levels. - Active ocular infection: postpone implantation until infection resolves. - Glaucoma history: use with caution and monitor IOP closely. - Known corticosteroid hypersensitivity: avoid use in allergic patients. - Systemic corticosteroid exposure: evaluate cumulative steroid load. - Store at controlled room temperature: keep in original packaging, protect from light and moisture.

Iluvien may interact with other ocular or systemic therapies.

Major Interactions (Avoid): - Concurrent intravitreal corticosteroids: increased risk of elevated intraocular pressure. - Systemic immunosuppressants: heightened susceptibility to ocular infections.

Moderate Interactions (Monitor Closely): - Topical non‑steroidal anti‑inflammatory drugs: potential corneal complications. - Antifungal or antiviral eye drops: may affect healing post‑implantation. - Systemic CYP3A4 inhibitors: possible alteration of corticosteroid metabolism.